Drug Trial Radar · NCT01236430
A Study to Determine the Bioequivalence of SCH 900068 Compared to Marketed Products (Protocol No. P07551)
Last checked: Nov 19, 2026Latest source record: Feb 16, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
200
Actual
Start
Feb 2011
Primary completion
Nov 2011
Study completion Feb 2012
Sponsor
- Lead sponsor
- Organon and CoIndustry
- Sponsor type
- Industry
- First posted
- Nov 8, 2010
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Crossover
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The intent of this study is to demonstrate that single doses of the Final Market Image (FMI) ezetimibe/atorvastatin 10mg/10mg and 10mg/80mg fixed dose combination (FDC) tablets are bioequivalent to the same doses of ezetimibe (ZETIA®) and atorvastatin (LIPITOR®) that are coadministered as individual tablets in healthy adults.
Conditions
- Hyperlipidemia
Interventions
EzetimibeDrug
Ezetimibe 10mg tablet given orally after an overnight fast (at least 10 hours).
Ezetimibe/atorvastatin 10mg/10mg FDCDrug
Ezetimibe/atorvastatin 10mg/10mg FDC tablet given orally after an overnight fast (at least 10 hours).
Atorvastatin 10mgDrug
Atorvastatin 10mg given orally after an overnight fast (at least 10 hours).
Atorvastatin 80mgDrug
Atorvastatin 80mg tablet given orally after an overnight fast (at least 10 hours).
Ezetimibe/atorvastatin 10mg/80mg FDCDrug
Ezetimibe/atorvastatin 10mg/80mg FDC tablet given orally after an overnight fast (at least 10 hours).
Primary outcomes
What the sponsor says the trial is designed to measure.
- Area under the concentration-time-curve from time zero to infinity (AUC0-∞) of atorvastatinTime frame: Hour 0 to Hour 48
- Maximum plasma concentration (Cmax) of atorvastatinTime frame: Hour 0 to Hour 48
- Area under the concentration time-curves from time zero to the time of last measured concentration (AUC0-last) of unconjugated ezetimibe (EZ)Time frame: Hour 0 to Hour 96
- Maximum plasma concentration (Cmax) of unconjugated ezetimibe (EZ)Time frame: Hour 0 to Hour 96
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.